OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

If you look at MMJ stocks across the Board, and the gaps and volume in the ones that are undervalued, you probably come to the conclusion that these new investors are not researching cannabis, they are actually smoking it. All kidding aside, what I believe is actually happening is that we are witnessing a major Sector Rotation into MMJ Stocks. (http://www.investopedia.com/terms/s/sectorrotation.asp).

Trigger 1: Bipartisan Support in Congress to allow Banking in MJ/MMJ and remove cannabis from DEA Schedule 1 to allow unhindered R&D: https://blumenauer.house.gov/cannabis-caucus. Big Banking and Big Pharma are now eyeing MMJ.

Trigger 2: MMJ ETF likely by April: http://nypost.com/2017/02/17/medical-marijuana-has-gone-corporate/. Lots of new investors scanning the AgroSphere Index for hidden gems and buyout targets.

The writing on the wall is as clear as day to me. MMJ is the next big thing. MMJ is not the next Green Wave, it's the Green Tsunami.

Throw your regular trading strategy out the window and instead look for MMJ's that have patent-protected IP and/or an MMJ Pipeline, ideally in cancers. Look for companies like $OWCP, which has 2 ready-to-market delivery systems - sublingual tablet and topical cream - and 2 others in development and a MMJ Pipeline that includes Psoriasis, PTSD, Migraines, and Multiple Myeloma. http://www.owcpharma.com/wp-content/uploads/2017/02/OWC-Feb-2017-ADV.pdf

What $OWCP has is worth Billions to Big Pharma companies like GILD, that have a dwindling pipeline and a mountain of cash.

Now that the MMJ Sector Rotation has started, the game now is identifying the MMJ stocks that will be gobbled up by Big Pharma. Mark my words: articles in cannabis magazines today are about MJ company's acreage and the price per gram, but in a month the articles will all be about the valuations of MMJ company's IP and Pipelines.

The Green Tsunami is coming and it's going to be a multi Billion dollar M&A spree fueled by promises of streamlined FDA approvals, repatriated offshore dollars, and deep pocketed Big Pharm companies desperate to beef up dwindling drug pipelines.